Key Highlights

  • Shares trading down 9.85%, losing $8.67 to reach $79.38
  • Second-quarter Revenue of $171.7 million topped estimates of $168.5 million
  • Net income of $74.7 million was driven by a 31% quarter-over-quarter surge in YUTREPIA sales
  • Decline comes amid profit-taking after the stock's roughly 180% year-to-date run-up and near 52-week highs
  • Investors are also digesting heavy insider selling, with 117 insider sales versus 1 purchase over six months
  • Management reaffirmed its target of exceeding $1 billion in 2027 net revenue

Shares Fall Despite Strong Quarterly Results

Liquidia (NASDAQ:LQDA) shares are tumbling nearly 10% today, down 9.85% to $79.38, despite the company reporting strong second-quarter 2026 results, with revenue of $171.7 million topping estimates of $168.5 million and Net Income of $74.7 million driven by a 31% quarter-over-quarter surge in YUTREPIA sales. The sell-off appears driven by profit-taking after the stock's massive run-up of roughly 180% year-to-date and near 52-week highs, as investors also digest heavy insider selling, with 117 insider sales versus just 1 purchase over the past six months.

Liquidia Corporation is a Morrisville, North Carolina-based biopharmaceutical company focused on developing, manufacturing, and commercializing therapies for rare cardiopulmonary diseases, particularly pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its lead product, YUTREPIA, an inhaled dry powder formulation of treprostinil built on the company's proprietary PRINT particle-engineering technology, received full FDA approval in 2025 and now drives the majority of company revenue following its late-stage commercial launch.

Guidance Reaffirmed Despite the Pullback

Management guided that R&D expense in the second half of 2026 will double from the first half, increasing again in 2027 to support the pipeline including clinical studies underway or planned for YUTREPIA and L606, while SG&A will also rise with commercial scaling. Despite this increased investment, the company expects to continue growing profitability. CEO Roger Jeffs stated confidence in exceeding $1 billion in net revenue in 2027, citing linear growth in referrals and new patient starts since launch, with the inhaled prostacyclin market growing to $607 million in the second quarter, up 6% quarter-over-quarter, and YUTREPIA approaching 30% of that market on a net revenue basis.

Liquidia also markets a generic treprostinil injection in the U.S. and is advancing L606, a liposomal treprostinil formulation in Phase III trials, while continuing to navigate Patent litigation with competitor United Therapeutics. The company ended the quarter with $284.2 million in cash, up $61.4 million from the first quarter and $93.5 million since the start of the year.

Conclusion

Liquidia's 9.85% decline today reflects profit-taking after a massive year-to-date rally rather than any deterioration in the underlying business, with revenue and net income both showing strong sequential growth driven by accelerating YUTREPIA sales. With management reaffirming its target of exceeding $1 billion in 2027 net revenue and continued pipeline Investment planned, the stock's next moves will likely hinge on whether YUTREPIA's referral and patient-start momentum continues to justify its elevated valuation.